Author

Xingli Shan

Observed name: Shan, Xingli

Institution: Cancer Hospital of Huanxing Chaoyang District Beijing

Observed institution: Cancer Hospital of Huanxing Chaoyang District Beijing

ORCID: 0000-0003-0861-0789

Observed ORCID: 0000-0003-0861-0789

OpenAlex ID: A5031585973

First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study

2024 · Longbin Xiong, Xingli Shan, et al. · Journal of the National Comprehensive Cancer Network · 12

Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study

2022 · Youyan Guan, Xiaobing Wang, et al. · BMC Medical Genomics · 8

Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report

2021 · Linjun Hu, Xingli Shan, et al. · OncoTargets and Therapy · 6

Efficacy and safety of tislelizumab combined with chemotherapy for locally advanced penile cancer: a prospective, single-arm clinical study

2025 · Xingli Shan, Hongsong Bai, et al. · British Journal of Cancer · 2

Albumin-bound paclitaxel, cisplatin, and bleomycin combination with tislelizumab for stage IV squamous cell carcinoma of the penis without surgical indications: A single-arm, single-center prospective phase II clinical study.

2024 · Xingli Shan, Hongsong Bai, et al. · Journal of Clinical Oncology · 2

Study on prevention of recurrence in patients with NMIBC for whom BCG vaccine treatment failed by hematoporphyrin intravesical perfusion photodynamic therapy (PDT) combined with intravesical perfusion therapy.

2025 · Linjun Hu, Chengming Xie, et al. · Journal of Clinical Oncology · 1

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer

2020 · Linjun Hu, Qinxin Zhao, et al. · Cancer Management and Research · 1

Modified docetaxel regimen for prostate cancer patients who got poor tolerance to chemotherapy

2017 · Linjun Hu, Changling Li, et al. · Zhonghua miniao waike zazhi · 1

Cognitive fusion targeted biopsy is not inferior to systematic biopsy in metastatic prostate cancer: a single-center, paired study

2026 · Yonghai Chen, Xingli Shan, et al. · BMC Urology

Real-world PSA kinetics and depth of response with ARPI-based triplet therapy in metastatic hormone-sensitive prostate cancer: A single-center retrospective cohort analysis.

2026 · Yonghai Chen, Huoshan Ning, et al. · Journal of Clinical Oncology

Analysis of the relationship between the number of hematoporphyrin intravesical perfusion photodynamic therapy (PDT) combined with intravesical perfusion therapy with tumor recurrence and progression in non-muscle-invasive bladder cancer (NMIBC).

2025 · Chengming Xie, Xingli Shan, et al. · Journal of Clinical Oncology

Analysis of the results of intravesical perfusion therapy combined with immediate or non-immediate hematoporphyrin intravesical perfusion photodynamic therapy (PDT) after TURBT for NMIBC.

2025 · Linjun Hu, Chengming Xie, et al. · Journal of Clinical Oncology

Additional file 2 of Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study

2022 · Guan, Youyan, Wang, Xiaobing, et al. · Figshare

Additional file 1 of Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study

2022 · Guan, Youyan, Wang, Xiaobing, et al. · Figshare

Works count: 15

Citation count: 33

H-index: 3

I10-index: 1